BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Doctor's orders: Eat ice cream, and other tips for a long and healthy life - 2Bayer sues COVID vaccine makers over mRNA technology
- 3Belarusian parliament passes a bill to crack down on LGBTQ+ rights
- 4Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
- 5Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- Germany paves the way for tighter EU asylum rules
- Instructions to Warmly greet Certainty and Appeal
- Finding the Force of Mentorship: Self-awareness Through Direction
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
- This Week In Space podcast: Episode 189 — Privatizing Orbit
- The Significance of Prenuptial Arrangements in Separation Procedures
- An Extended period of Voyaging Carefully: the World with Reason
